AstraZeneca Gets Accelerated FDA Nod for Ultomiris in IgA Nephropathy
FROM THE WIRE · FINANCE.YAHOO.COM
AstraZeneca AZN announced that the FDA has approved its blockbuster rare disease drug, Ultomiris (ravulizumab), for reducing proteinuria (protein in urine) in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk for disease progression. Following the latest…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishRegulatory approval for a key drug, though accelerated and shares are down year to date.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01The FDA approved Ultomiris to reduce proteinuria in adults with IgA nephropathy at risk of progression.
- 02It is the first and only C5 complement inhibitor approved in the US for this indication.
- 03It has not yet been established whether it slows kidney function decline.
- 04AstraZeneca shares are down 7.4% year to date.
NEWS IMPACT AND MARKET REACTIONChange from the reference price
AstraZeneca PLC172.57 USD-0.40%today +2.45%Positive Novartis AG155.94 USD-0.27%today +1.30%Neutral Travere Therapeutics, Inc.52.92 USD+0.70%today +0.65%Neutral
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets